Drug Profile
GSK 2800528
Alternative Names: GSK2800528Latest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Anti-inflammatories; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation; Psoriasis
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in United Kingdom (SC)
- 28 Jul 2018 No recent reports of development identified for phase-I development in Psoriasis(In volunteers) in United Kingdom (SC)
- 01 Apr 2014 GlaxoSmithKline completes a phase I trial in Inflammation and Psoriasis (in volunteers) in United Kingdom (NCT01899755)